← Back to Screener
Olema Pharmaceuticals, Inc. Common Stock (OLMA)
Price$16.58
Favorite Metrics
Price vs S&P 500 (26W)50.38%
Price vs S&P 500 (4W)9.97%
Market Capitalization$1.47B
All Metrics
Book Value / Share (Quarterly)$5.88
P/TBV (Annual)3.88x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.80
Price vs S&P 500 (YTD)-36.86%
EPS (TTM)$-1.86
10-Day Avg Trading Volume0.84M
EPS Excl Extra (TTM)$-1.86
EPS (Annual)$-1.87
ROI (Annual)-33.73%
Cash / Share (Quarterly)$6.21
ROA (Last FY)-30.45%
EBITD / Share (TTM)$-2.05
ROE (5Y Avg)-36.34%
Cash Flow / Share (Annual)$-1.80
P/B Ratio3.06x
P/B Ratio (Quarterly)4.11x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-36.49x
ROA (TTM)-38.74%
EPS Incl Extra (Annual)$-1.87
Current Ratio (Annual)9.95x
Quick Ratio (Quarterly)9.85x
3-Month Avg Trading Volume1.76M
52-Week Price Return294.84%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.04
52-Week High$36.26
EPS Excl Extra (Annual)$-1.87
26-Week Price Return59.13%
Quick Ratio (Annual)9.85x
13-Week Price Return-41.54%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)9.95x
Enterprise Value$1,420.679
Book Value / Share Growth (5Y)-7.33%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$6.21
3-Month Return Std Dev79.38%
Net Income / Employee (TTM)$-1
ROE (Last FY)-33.95%
EPS Basic Excl Extra (Annual)$-1.87
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-1.86
ROI (TTM)-42.65%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.90
Price vs S&P 500 (52W)259.74%
Year-to-Date Return-32.72%
5-Day Price Return5.59%
EPS Normalized (Annual)$-1.87
ROA (5Y Avg)-33.34%
Month-to-Date Return12.81%
Cash Flow / Share (TTM)$-2.30
EBITD / Share (Annual)$-2.05
LT Debt / Equity (Annual)0.01x
ROI (5Y Avg)-36.30%
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$-1.86
P/TBV (Quarterly)2.79x
P/B Ratio (Annual)4.11x
Book Value / Share (Annual)$5.88
Price vs S&P 500 (13W)-44.40%
Beta2.21x
Revenue / Share (TTM)$0.00
ROE (TTM)-42.90%
52-Week Low$3.89
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.33
4.29
4.33
4.26
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
OLMAOlema Pharmaceuticals, Inc. Common Stock | — | — | — | — | $16.58 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on targeted therapies for women's cancers. Its pipeline includes OP-1250, which has completed preclinical studies, and OP-3136. The company aims to improve outcomes for women living with cancer.